PRESENTATION

Q2 2026 — Presentation

Q2 2026PDF · 15 pages2.8 MB
Elevance Health
2Q 2026 Supplemental
Earnings Presentation
July 15, 2026

-- 1 of 15 --

2
Key Highlights
1 2Q 2026
Results
Results exceeded our outlook, supported by strong operating performance across our diversified portfolio
• Adjusted diluted EPS 1 of $7.45 reflects favorable benefit expense performance and net below -the -line benefit of $0.80
• Operating revenue of $49.8B increased 0.8% due to higher premium yields and CarelonRx product revenue, partially
offset by anticipated membership declines
• Benefit expense ratio of 89.7% was better than expected, led by Medicare Advantage and Individual ACA
2 2026 Outlook Raising 2026 adjusted diluted EPS guidance to at least $27.00, supported by operating strength while maintaining
appropriate prudence
• Non -recurring below -the -line benefit will fund targeted one -time investments in medical cost management, member
experience, provider connectivity, operating efficiency, and Carelon
• Revenue and benefit expense ratio guidance unchanged; adjusted operating expense ratio to be in upper half of range
• Medicaid performance supports our unchanged full -year margin guidance, which remains appropriately prudent
• Raising operating cash flow guidance to at least $6.0 billion
Expect to return to at least 12% adjusted diluted EPS growth in 2027 , off our revised 2026 earnings baseline of $26.00 2
3 Strategic
Focus Areas
Executing with discipline across our diversified portfolio to support durable enterprise performance
Managing Medicaid within our full -year margin framework, while advancing rate alignment, targeted cost -of-care actions,
and Carelon -enabled support for complex populations
Accelerating targeted investments to strengthen medical cost management, member experience, provider connectivity,
operating efficiency, and Carelon’s value -based capabilities
Detecting cost trend earlier and with greater precision through clinical oversight, payment integrity, and faster execution
Simplifying the member experience with tools to navigate benefits, manage chronic conditions, and close gaps in care
1. See “GAAP Reconciliation” on slides 13 and 14 herein.
2. 2026 Earnings Baseline excludes non -recurring NII recognized in Q1 and the net below -the -line benefit in Q2 as well as targeted one -time investments.

-- 2 of 15 --

33
Medical Cost
Management
• Detect emerging cost
trends earlier
• Deploy targeted
clinical, network, and
operating actions
faster
• Execute cost -of-care
initiatives with
greater precision
Member
Engagement
• Guide members with
personalized, real -
time support
• Manage chronic
conditions with
tailored care plans
• Anticipate member
needs and identify
gaps in care
Provider
Connectivity
• Support informed,
timely clinical decisions
through collaboration
• Reduce administrative
friction, documentation
requests, and
avoidable denials
• Speed alignment on
care decisions
Carelon
• Expand CareBridge to
new markets
• Grow external client
relationships
• Launch new
integrated, value -
based care solutions
Driving better outcomes,
lower costs, and more
consistent performance
Lower
healthcare
costs
Improve
member
experience
Reduce
provider
friction
Scale
value -based
solutions
Accelerating Targeted Investments to Strengthen Durable
Operating Performance

-- 3 of 15 --

44
Raised 2026 Adjusted Diluted EPS Guidance To At Least $27.00
2026 Adjusted Diluted EPS Guidance 1 2026 Seasonality
>$25.75 ~$0.25
~$0.80
~($0.25)
~($0.80)
~$0.25 >$26.00
~$1.00 >$27.00
1Q 2026
Earnings
Baseline
2Q
Seasonality
2H
Seasonality
2Q Operating
Strength
Updated 2026
Earnings
Baseline
1Q
Non-Recurring
NII Benefit
2Q Non-
Recurring
Below-the-Line
Benefit
Targeted
One-time
Investments
Current 2026
Adjusted EPS
Guidance
1H,
~74%
3Q,
~17%
4Q, ~9%
2026 Adjusted EPS
Guidance
>$27.00
Guidance raise reflects second quarter operating strength; non -recurring below -the -line favorability funds targeted one -time investments
1. Adjusted EPS refers to Adjusted Diluted Earnings Per Share. See “GAAP Reconciliation” on slides 13 and 14 herein.
2. 2026 FY Earnings Baseline as of April 22, 2026
3. Updated 2026 Earnings Baseline excludes non -recurring NII recognized in Q1 and the net below -the -line benefit in Q2 as well as t argeted one -time investments.
4. Current 2026 Adjusted Diluted EPS Guidance as of July 15, 2026.
2 4
Offsetting items:
3
Offsetting items:

-- 4 of 15 --

55
Key Highlights
• Second quarter adjusted diluted EPS
exceeded our outlook, reflecting
favorable benefit expense performance
and disciplined execution
• Adjusted EPS of $7.45 was supported by
strong operating results and an
approximately $0.80 per share net
below -the -line benefit
• Operating revenue growth was driven
by higher premium yields and CarelonRx
product revenue, partially offset by
anticipated membership declines
• Benefit expense ratio of 89.7% was
better than expected, led by Medicare
Advantage and Individual ACA;
elevated Medicaid trend remains
contemplated in our full -year guidance
• Operating cash flow of $1.9B reflects the
timing of state Medicaid payments and
operating strength; raising 2026
guidance to at least $6.0 billion
2Q 2026 Results
Elevance Health 2Q 2026 2Q 2025 Change
Operating Revenue 1 $49.8B $49.4B 0.8%
Benefit Expense Ratio 89.7% 88.9% 80 bps
Adjusted Operating Expense Ratio 2 11.0% 10.0% 100 bps
Adjusted Operating Gain 1,2 $1.8B $2.5B (26.9%)
Adjusted Operating Margin 1,2 3.6% 5.0% (140) bps
Net Investment Income $704M $486M 44.9%
Adjusted Diluted EPS 2 $7.45 $8.84 (15.7%)
Operating Cash Flow $1.9B $2.1B ($0.1B)
1. See “Non -GAAP Measures and Basis of Presentation” on slide 12 herein.
2. See “GAAP Reconciliation” on slides 13 and 14 herein.

-- 5 of 15 --

66
Key Highlights
• Health Benefits performed better than
our outlook, reflecting execution across
our diversified portfolio
• Operating revenue grew 2.7% year over
year, driven by higher premium yields,
partially offset by intentional actions to
reposition our Medicare Advantage and
Employer Group risk businesses, and
Medicaid membership attrition
• Operating margin of 2.1% was better than
expected; year -over -year decline reflects
anticipated Medicaid trend and targeted
incremental investments, partially offset
by favorable performance in Medicare
Advantage and Individual ACA
• Membership of 44.9M reflects a known
commercial fee -based customer
transition and anticipated attrition in our
Individual ACA and Medicaid
membership
Health Benefits 2Q 2026 2Q 2025 Change
Operating Revenue 1 $42.7B $41.6B 2.7%
Operating Gain 1,2 $0.9B $1.6B (42.6%)
Operating Margin 1,2 2.1% 3.8% (170) bps
Membership 44.9M 45.6M (1.5%)
1. See “Non -GAAP Measures and Basis of Presentation” on slide 12 herein.
2. See “Reportable Segment Highlight & Health Benefits Revenue Details” on slide 15 herein.
Health Benefits
2Q 2026 Results

-- 6 of 15 --

77
Key Highlights
• Carelon’s performance was consistent
with expectations as we scale value -
based solutions for members with
complex and chronic needs
• CarelonRx operating revenue benefited
from higher revenue per adjusted script,
partly offset by lower script volumes due
to health plan membership attrition;
operating margin reflects improved
profitability in specialty pharmacy
• Carelon Services operating revenue
supported by continued scaling of its risk -
based solutions; operating margin
impacted by ongoing investment in the
expansion of risk -based solutions
2Q 2026 Results
Carelon 2Q 2026 2Q 2025 Change
Operating Revenue 1 $19.2B $18.1B 6.3%
Operating Gain 1,2 $0.9B $0.9B 1.3%
Operating Margin 1,2 4.9% 5.2% (30) bps
Adjusted Scripts 80.9M 83.3M (2.9%)
Consumers Served 92.4M 97.3M (5.0%)
1. See “Non -GAAP Measures and Basis of Presentation” on slide 12 herein.
2. See “Reportable Segment Highlight & Health Benefits Revenue Details” on slide 15 herein.
Health Services

-- 7 of 15 --

88
Flywheel Supports Our Long -Term Growth Algorithm
Health Benefits
Optimize
the Core
Invest in
Growth
Accelerate
Performance
Targeting at least 12% average annual growth in
Adjusted Diluted Earnings Per Share
Approximately 45M medical members
balanced across commercial, Medicaid,
Medicare, and the Federal Employee
Program, leveraging the assets and
capabilities of Carelon to accelerate
growth
As an integrated portfolio of whole
health solutions serving approximately
92M consumers, Carelon connects care
across physical, behavioral, social,
home health, and pharmacy needs to
bend the cost curve, enhance consumer
experiences, and deliver whole health,
affordably
Health Services

-- 8 of 15 --

99
Adjusted Operating Gain – High Single Digit to Low Double Digit CAGR 1
Long -Term Growth Algorithm
Revenue Growth
High Single Digit CAGR 1
Adjusted Operating Margin
Expanding to 5.0% – 6.0%
Capital Deployment
Approximately 4% Contribution to
Adjusted Diluted EPS CAGR 1
Health Benefits
Mid to High Single Digit CAGR
Driven by targeted membership growth, strategic
geographic and product expansion, and growth in
specialized populations
Carelon Services
High Teens to Low Twenties CAGR
Driven by risk -based revenue growth and M&A
CarelonRx
Low Double Digit CAGR
Driven by new client relationships and scaling of
specialty pharmacy capabilities
Strengthen operational
discipline to accelerate margin
normalization
Advance value -based care
models to improve outcomes
and reduce costs
Integrate technology to simplify
the experience for members and
care providers
Share Repurchases
Organic Reinvestment
Programmatic M&A targeting
integrated solutions that
strengthen health plan
competitiveness
+ +
1. CAGR = Compound Annual Growth Rate Target.
Targeting at least 12% average annual growth in Adjusted Diluted EPS

-- 9 of 15 --

10	10
Committed to Strong Growth Over the Long -Term
M&A/ Organic
Reinvestment
50%
Share
Repurchase
30%
Dividends
20%
3.8%
5.0% – 6.0%
2025 Target
$198B
High Single
Digit CAGR 1
2025 Target
Elevance Health
4.8%
Mid Single
Digit
2025 Target
$72B
Mid Teens
CAGR 1
2025 Target
Carelon 2
2.5%
Mid Single
Digit
2025 Target
$167B
Mid to High
Single Digit
CAGR 1
2025 Target
Health Benefits
Capital
Allocation
Targeting at least 12% average annual
growth in Adjusted Diluted EPS
Adjusted 3
Operating
Margin
Revenue
(in billions)
1. CAGR = Compound Annual Growth Rate Target.
2. The CAGR target for revenue and the operating margin target for Carelon includes: ( i) a low double digit revenue CAGR and mid single digit percentage operating margin for
CarelonRx, and (ii) a high teens to low twenties revenue CAGR and mid to high single digit percentage operating margin for Ca rel on Services.
3. See “GAAP Reconciliation” on slides 13 and 14 herein.

-- 10 of 15 --

11
Forward -Looking Statements
This document contains certain forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward -looking statements reflect our views
about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believ e,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,”
“project,” “forecast,” “plan,” “potential,” “predict” and similar expressions are intended to identify forward -looking statement s. These statements include, but are not limited to:
financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and
services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many o f which are difficult to predict and generally beyond
our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the fo rwa rd -looking statements. You are cautioned not to place
undue reliance on these forward -looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other
disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect
our business. Except to the extent required by law, we do not update or revise any forward -looking statements to reflect events or circumstances occurring after the date hereof.
These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enro llm ent; our ability to secure and implement sufficient
premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catas trophes; the impact of new or changes in existing
federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmac y services and other diversified products and services,
or their enforcement or application; the impact of cyber -attacks or other privacy or data security incidents or our failure to c omply with any privacy, data or security laws or
regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and moderniz e o ur information systems, or failure of our information
systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availab ility and integrity of our data; changes in economic and
market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pre ssu res and our ability to adapt to changes in the industry
and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, i ncl uding those related to non -compliance with
the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Se rvices Star Ratings and other quality scores
and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mi x; costs and other liabilities associated with litigation,
government investigations, audits or reviews; our ability to contract with providers on cost -effective and competitive terms; ri sks associated with providing healthcare, pharmacy
and other diversified products and services, including medical malpractice or professional liability claims and non -compliance b y any party with the pharmacy services agreement
between us and CaremarkPCS Health, L.L.C.; the effects of any negative publicity or sentiment related to the health benefits industry in general or us i n particular; risks associated
with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and
other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required mi nim um levels of capital; our ability to repurchase shares
of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other conside rat ions; the potential negative effect from our
substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact o ur access to or further increase the cost of financing; a
downgrade in our financial strength ratings; events that may negatively affect our licenses with the Blue Cross and Blue Shie ld Association; intense competition to attract and retain
employees; risks associated with our international operations; and various laws and provisions in our governing documents tha t may prevent or discourage takeovers and business
combinations.

-- 11 of 15 --

12
Non -GAAP Measures and Basis of Presentation
This document references non -GAAP measures, including “Adjusted Diluted EPS,” “Adjusted Operating Expense Ratio,” “Adjusted Oper ating Gain,” “Adjusted Operating Margin,”
“Adjusted Shareholders’ Net Income,” and “Adjusted Operating Expense”. These non -GAAP measures are intended to aid investors wh en comparing Elevance Health’s financial
results among periods and are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliati ons of these non -GAAP measures to the most
directly comparable measures calculated in accordance with GAAP are available on slides 13 -14 of this document.
In addition to these non -GAAP measures, references are made to the measures “Operating Revenue,” “Operating Gain/Loss,” and “Ope rating Margin”. Operating revenue and
operating gain/loss are the key measures used by management to evaluate performance in each of its reportable segments, alloc ate resources, set incentive compensation
targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benef it expense, cost of products sold and operating
expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible assets and gains/losses on
extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the res ponsibility of operating segment
management. Each of these measures is provided to further aid investors in understanding and analyzing Elevance Health’s oper ati ng and financial results. A reconciliation of
reportable segments operating gain to income before income tax expense is available on slide 13 of this document. Prior amoun ts may be grouped differently to conform to the
current presentation.

-- 12 of 15 --

13	13
GAAP Reconciliation — Shareholders’ Net Income and Shareholders’
Earnings Per Diluted Share Three Months Ended Jun 30 Six Months Ended Jun 30
(In millions, except per share data) 2026 2025 Change 2026 2025 Change
Shareholders' net income $1,463 $1,743 (16.1%) $3,227 $3,926 (17.8%)
Add / (Subtract):
Amortization of other intangible assets 110 147 222 302
Net losses on financial instruments 1 56 131 134 595
Transaction and integration related costs 1 44 53 91 133
Litigation and settlement expenses 1 11 10 18 15
Accrual related to CMS notice 1,2 — — 935 —
Business optimization program charges 1 — — 129 —
Tax impact of non -GAAP adjustments (60) (87) (360) (255)
Net adjustment items 161 254 1,169 790
Adjusted shareholders' net income $1,624 $1,997 (18.7%) $4,396 $4,716 (6.8%)
Shareholders’ earnings per diluted share $6.71 $7.72 (13.1%) $14.73 $17.33 (15.0%)
Add / (Subtract):
Amortization of other intangible assets 0.50 0.65 1.01 1.33
Net losses on financial instruments 1 0.26 0.58 0.61 2.63
Transaction and integration related costs 1 0.20 0.23 0.42 0.59
Litigation and settlement expenses 1 0.05 0.04 0.08 0.07
Accrual related to CMS notice 1,2 — — 4.27 —
Business optimization program charges 1 — — 0.59 —
Tax impact of non -GAAP adjustments (0.28) (0.39) (1.64) (1.13)
Net adjustment items 0.74 1.12 5.33 3.49
Adjusted shareholders’ earnings per diluted share 3 $7.45 $8.84 (15.7%) $20.06 $20.82 (3.7%)
Three Months Ended Jun 30 Six Months Ended Jun 30
(In millions) 2026 2025 Change 2026 2025 Change
Income before income tax expense $1,937 $2,292 (15.5%) $4,241 $5,089 (16.7%)
Net investment income (704) (486) (1,469) (1,076)
Interest expense 364 341 721 685
Amortization of other intangible assets 110 147 222 302
Net losses on financial instruments 56 131 134 595
Reportable segments operating gain $1,763 $2,425 (27.3%) $3,849 $5,595 (31.2%)
1. Adjustment item resides in the Corporate & Other reportable segment
2. Adjustment item represents the Company's current best estimate of the identified potential exposure for certain historical Me dic are Advantage risk adjustment data related to the CMS notice to the Company dated February 27, 2026.
3. Totals may not foot due to rounding.

-- 13 of 15 --

14	14
GAAP Reconciliation — Operating Gain, Operating Expense Ratio, and
2026 Outlook
(In millions)
Operating expense $5,547 $4,997 11.0% $11,877 $10,297 15.3%
Add / (Subtract):
Transaction and integration related costs 1 (44) (53) (91) (133)
Litigation and settlement expenses 1` (11) (10) (18) (15)
Accrual related to CMS notice 1,2 — — (935) —
Business optimization program charges 1 — — (129) —
Net adjustment Items (55) (63) (1,173) (148)
Adjusted operating expense $5,492 $4,934 11.3% $10,704 $10,149 5.5%
Operating revenue $49,826 $49,421 0.8% $99,320 $98,186 1.2%
Operating expense ratio 11.1% 10.1% 100 bp 12.0% 10.5% 150 bp
Adjusted operating expense ratio 11.0% 10.0% 100 bp 10.8% 10.3% 50 bp
Three Months Ended Jun 30 Six Months Ended Jun 30
(In millions) 2026 2025 Change 2026 2025 Change
Reportable segments operating gain $1,763 $2,425 (27.3%) $3,849 $5,595 (31.2%)
Add / (Subtract):
Transaction and integration related costs 1 44 53 91 133
Litigation and settlement expenses 1 11 10 18 15
Accrual related to CMS notice 1,2 — — 935 —
Business optimization program charges 1 — — 129 —
Net adjustment Items 55 63 1,173 148
Reportable segments adjusted operating gain $1,818 $2,488 (26.9%) $5,022 $5,743 (12.6%)
Full Year 2026 Outlook
Shareholders’ earnings per diluted share At least $20.10
Add / (Subtract):
Accrual related to CMS notice 1,2 $4.27
Amortization and other intangible assets 3 $2.00
Net losses on financial instruments 3 $1.15
Transaction and integration related costs 1,3 $0.90
Business optimization program charges 1 $0.59
Litigation and settlement expenses 1,3 $0.10
Tax impact of non -GAAP adjustments 3 Approximately ($2.11)
Net adjustment items $6.90
Adjusted shareholders’ earnings per diluted share At least $27.00
1. Adjustment item resides in the Corporate & Other reportable segment.
2. Adjustment item represents the Company's current best estimate of the identified potential exposure for certain historical Me dic are Advantage risk adjustment data related to the CMS notice to the Company dated February 27, 2026.
3. Adjustment item represents the midpoint of a projected range and serves as the estimated full year adjustment amount.
Operating revenue $49,826 $49,421 0.8% $99,320 $98,186 1.2%
Operating margin 3.5% 4.9% (140) bp 3.9% 5.7% (180) bp
Adjusted operating margin 3.6% 5.0% (140) bp 5.1% 5.8% (70) bp

-- 14 of 15 --

15	15
Reportable Segment & Health Benefits Revenue Details
Three Months Ended Jun 30 Six Months Ended Jun 30
(In millions, Unaudited) 2026 2025 Change 2026 2025 Change
Operating Revenue
Health Benefits $42,720 $41,582 2.7% $85,210 $83,013 2.6%
CarelonRx 11,250 10,643 5.7% 21,850 20,759 5.3%
Carelon Services 7,975 7,441 7.2% 15,340 13,977 9.8%
Corporate & Other 6 232 (97.4%) 10 397 (97.5%)
Eliminations (12,125) (10,477) NM6 (23,090) (19,960) NM6
Total Operating Revenue 1 $49,826 $49,421 0.8% $99,320 $98,186 1.2%
Operating Gain (Loss)
Health Benefits $896 $1,560 (42.6%) $3,053 $3,777 (19.2%)
CarelonRx 582 536 8.6% 1,164 1,138 2.3%
Carelon Services 366 400 (8.5%) 836 891 (6.2%)
Corporate & Other 2,3 (81) (71) NM6 (1,204) (211) NM6
Total Operating Gain 1,4 $1,763 $2,425 (27.3%) $3,849 $5,595 (31.2%)
Operating Margin
Health Benefits 2.1% 3.8% (170) bp 3.6% 4.5% (90) bp
CarelonRx 5.2% 5.0% 20 bp 5.3% 5.5% (20) bp
Carelon Services 4.6% 5.4% (80) bp 5.4% 6.4% (100) bp
Total Operating Margin 1 3.5% 4.9% (140) bp 3.9% 5.7% (180) bp
1. See “Basis of Presentation” on slide 12 herein.
2. Operating Gain for the three and six months ended June 30, 2026 included $44 and $91 million, respectively, of transaction an d i ntegration related costs, and $11 and $18 million, respectively, of litigation and settlement expenses. Operating Gain for th e six months ended June 30, 2026 also included $935 million for the
Company's current best estimate of the identified potential exposure for certain historical Medicare Advantage risk adjustmen t data related to the CMS notice to the Company dated February 27, 2026, and $129 million of business optimization program charg es. All adjustments for the three and six month periods
reside in the Corporate & Other reportable segment.
3. Operating Gain for the three and six months ended June 30, 2025, included $53 and $133 million, respectively, of transaction and integration related costs and $10 and $15 million, respectively, of litigation and settlement expenses, which reside in the C orporate & Other reportable segment.
4. Operating Gain for the three and six months ended June 30, 2026, and June 30, 2025, include items excluded from adjusted shar eho lders' net income. See "GAAP Reconciliation" on pages 13 and 14 herein.
5. The Individual business, including ACA products, is reported as part of Commercial Operating Revenue.
6. "NM" = calculation not meaningful.
Elevance Health has four reportable segments: Health Benefits (comprised of Individual, Employer Group risk -based, Employer Grou p fee -based, BlueCard®, Medicare, Medicaid, and Federal Employee Program
businesses); CarelonRx; Carelon Services; and Corporate & Other (comprised of businesses that do not individually meet the qu ant itative thresholds for an operating division as well as corporate expenses not
allocated to our other reportable segments).
Three Months Ended Jun 30 Six Months Ended Jun 30
(In millions, Unaudited) 2026 2025 Change 2026 2025
Health Benefits Operating Revenue
Commercial $13,561 $12,453 8.9% $26,799 $24,805 8.0%
Individual 5 2,720 2,328 16.8% 5,260 4,689 12.2%
Medicare 10,962 11,446 (4.2%) 21,953 22,852 (3.9%)
Medicaid 14,444 13,911 3.8% 28,724 27,954 2.8%
Federal Employee Program 3,753 3,772 (0.5%) 7,734 7,402 4.5%
Total Health Benefits Operating Revenue 1 $42,720 $41,582 2.7% $85,210 $83,013 2.6%

-- 15 of 15 --